Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.69 - $5.17
Previous CloseN/A
Volume165.25K
Average Volume (3M)3.59M
Market Cap
$375.93M
Enterprise Value$154.35
Total Cash (Recent Filing)$235.67M
Total Debt (Recent Filing)$58.45M
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Aug 12, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume2,926,750
30 Day Avg. Volume3,585,683
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.33Price Target Upside253.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$22.84M
Bulls Say, Bears Say
Bulls Say
Strategic Pharma PartnershipA partnership with Roche provides durable scientific and commercial validation, non-dilutive near-term funding and potential milestone/royalty upside. That collaboration can accelerate modality development, broaden exit pathways, and de-risk programs beyond C4’s internal resources.
Multi-year Cash RunwayA reported cash balance funding operations through end-2028 materially reduces near-term financing pressure, allowing multiple clinical programs to progress. This runway creates time to achieve value-driving milestones or secure partner funding before needing dilutive capital raises.
Advancing Clinical PipelineProgression from fully enrolled Phase 1 into active Phase 2 and planned Phase 1b combinations demonstrates tangible pipeline advancement. Sustained clinical momentum increases likelihood of future registration or partnership catalysts and supports the company’s long-term strategy building targeted degrader assets.
Bears Say
High Cash BurnConsistent ~-$95M annual operating and free cash burn is a structural weakness: it consumes the cash runway and raises the probability the company will need additional financing before commercialization. That increases dilution risk and constrains long-term strategic flexibility if clinical timelines slip.
Deep Unprofitability And Low RevenueModest, choppy revenues and a deeply negative net margin indicate the business is still far from breakeven. As a clinical-stage biotech, commercial revenue is limited; sustained losses imply an extended timeline to profitability and continued dependence on partnerships and capital markets.
Balance-sheet Erosion & Negative ReturnsAlthough leverage is modest, declining equity/assets and a roughly -54% ROE signal capital erosion from operating losses. Continued negative returns reduce financial resilience, could worsen financing terms over time, and limit strategic options if losses persist.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.69 and its highest was $5.17 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $375.93M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 17 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.051.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.21.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 110,567,220 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.33 (253.88% Upside)
$10.33 (253.88% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 306.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$10.33
▲(253.88% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.97% Insiders
8.63% Mutual Funds
4.20% Other Institutional Investors
72.62% Public Companies and
Individual Investors